SENSHealthcare · Medical DevicesThe 7 Wall Street analysts covering Senseonics Holdings, Inc. hold a median 12-month price target of $14 — +44.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Senseonics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (77): Analysts have, on balance, been raising their forecasts.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SENS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +44.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 July 2026 | Mizuho | Maintains | Outperform | — |
| 12 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 May 2026 | Stifel | Maintains | Hold | — |
| 6 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Nov 2025 | Barclays | Maintains | Overweight | — |
| 5 Nov 2025 | TD Cowen | Maintains | Buy | — |
| 27 Aug 2025 | Barclays | Initiates | Overweight | — |
| 15 July 2025 | TD Cowen | Initiates | Buy | — |
| 8 July 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Apr 2025 | Mizuho | Initiates | Outperform | — |
| 5 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 July 2023 | Jefferies | Initiates | Underperform | — |
| 11 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 July 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2021 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SENS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 15% of US stocks
Cheaper than 21% of US stocks
Cheaper than 76% of US stocks
Higher than 94% of US stocks
Higher than 73% of US stocks
Higher than 10% of US stocks
Higher than 2% of US stocks
Higher than 11% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Senseonics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Senseonics Holdings raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
Why it matters — A watcher of Senseonics would care because the raised outlook and record organic gross margin signal improved operational and financial performance for the company.
Senseonics Holdings, Inc. held its Q2 2026 earnings call, and a transcript of the call was published via Seeking Alpha. The item announces the availability of the earnings call transcript for the company's second quarter of 2026.
Why it matters — A SENS watcher would look to this transcript for management's commentary and details on the company's second-quarter performance and outlook.
Senseonics Holdings reported a second-quarter loss of $0.63 per share, which was larger than the Zacks Consensus Estimate of a $0.55 loss, and also larger than the $0.40 per share loss reported in the same quarter a year ago. Revenue topped estimates.
Why it matters — A wider-than-expected quarterly loss signals weaker-than-forecast financial performance, which SENS watchers would monitor for signs of the company's profitability trajectory.
The 7 Wall Street analysts covering Senseonics Holdings, Inc. have a median 12-month price target of $14, with estimates ranging from $8 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Senseonics Holdings, Inc., 4 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Senseonics Holdings, Inc. 24 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Senseonics Holdings, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +44.2% from the last close, and Ticker Nerd's factor model ranks Senseonics Holdings, Inc. 24 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Senseonics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SENS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $18 over the next 12 months.
Senseonics Holdings, Inc. returned +11.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Senseonics Holdings, Inc. is a commercial-stage medical technology company specializing in long-term, implantable continuous glucose monitoring systems for people with diabetes in the United States and internationally.
The most recent item we track (MarketBeat, 7 Aug 2026): "Senseonics Holdings, Inc. Common Stock Q2 Earnings Call Highlights". Senseonics Holdings raised its full-year 2026 revenue and gross-margin outlook after reporting second-quarter revenue growth of approximately 120% and its highest organic gross margin to date.
Senseonics Holdings, Inc. is a commercial-stage medical technology company specializing in long-term, implantable continuous glucose monitoring systems for people with diabetes in the United States and internationally. The company’s Eversense product family, including Eversense, Eversense XL, Eversense E3, and Eversense 365, uses a small sensor inserted under the skin, a removable and rechargeable smart transmitter worn on the body, and a mobile application that delivers real-time glucose readings and alerts. These systems are designed to provide extended wear duration compared with traditional transcutaneous CGM devices, supporting continuous monitoring without frequent sensor replacement. Senseonics focuses on the development and manufacturing of these glucose monitoring products and distributes them through healthcare providers, distributors, and strategic commercial partners, serving the global diabetes community. Headquartered in Germantown, Maryland, Senseonics plays a specialized role in the medical technology and diabetes care market by offering differentiated implantable CGM solutions intended to support more informed and convenient day-to-day glucose management.
CEO Dr. Timothy T. Goodnow Ph.D. · 130 employees · United States · https://www.senseonics.com